Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP/Chief Scientific Officer | December 15, 2020 | December 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date December 15, 2020 · Filed December 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,907 |
Ending reported balance
After 2020-12-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-12-15 · Exercise / conversion · Acquired 10,000 · Balance 34,907 F1: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Row 2 · 2020-12-15 · Sale · Disposed 5,776 · Balance 29,131 F1: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F2: This transaction was executed in multiple trades at prices ranging from $62.18 to $63.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2020-12-15 · Sale · Disposed 4,024 · Balance 25,107 F1: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F3: This transaction was executed in multiple trades at prices ranging from $63.24 to $64.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2020-12-15 · Sale · Disposed 200 · Balance 24,907 F1: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.51 · Expires 2026-09-08 | Direct | 145,000 |
Reported balance
After 2020-12-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-15 · Exercise / conversion · Disposed 10,000 · Balance 145,000 F1: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F4: This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.
F2: This transaction was executed in multiple trades at prices ranging from $62.18 to $63.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $63.24 to $64.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2020 Filed Dec 17, 2020 23:58 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-20-012070 · edgar.xml · derivative · entry 5 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 10,000 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F4 · derivative.exercise_date: This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 23:58 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 200 | $64.39 | $12,878.00 |
DisclosureSEC source: 0001179110-20-012070 · edgar.xml · nonDerivative · entry 4 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,907 F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 23:58 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,024 | $63.84 | $256,892.16 |
DisclosureSEC source: 0001179110-20-012070 · edgar.xml · nonDerivative · entry 3 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,107 F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.24 to $64.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 23:58 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,776 | $62.74 | $362,386.24 |
DisclosureSEC source: 0001179110-20-012070 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,131 F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.18 to $63.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 23:58 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 10,000 | $16.51 | $165,100.00 |
DisclosureSEC source: 0001179110-20-012070 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:14 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-20-011830 · edgar.xml · derivative · entry 3 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 10,000 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F2 · derivative.exercise_date: This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:14 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $45.00 | $450,000.00 |
DisclosureSEC source: 0001179110-20-011830 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,907 F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:14 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 10,000 | $16.51 | $165,100.00 |
DisclosureSEC source: 0001179110-20-011830 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:12 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-20-011752 · edgar.xml · derivative · entry 3 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 20,000 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F3 · derivative.exercise_date: This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:12 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 20,000 | $40.02 | $800,400.00 |
DisclosureSEC source: 0001179110-20-011752 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,907 F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 21:12 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 20,000 | $16.51 | $330,200.00 |
DisclosureSEC source: 0001179110-20-011752 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:13 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 228 | $31.21 | $7,115.88 |
DisclosureSEC source: 0001179110-20-010963 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,907 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2020. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:38 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,000 | $31.39 | $94,170.00 |
DisclosureSEC source: 0001179110-20-010507 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,135 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.88 to $31.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:44 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-20-009170 · edgar.xml · derivative · entry 3 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 10,000 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F3 · derivative.exercise_date: This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:44 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $35.29 | $352,900.00 |
DisclosureSEC source: 0001179110-20-009170 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,135 F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:44 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 10,000 | $16.51 | $165,100.00 |
DisclosureSEC source: 0001179110-20-009170 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 238 | $34.99 | $8,327.62 |
DisclosureSEC source: 0001179110-20-008833 · edgar.xml · nonDerivative · entry 3 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,135 F2 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 6, 2020. The sale does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.69 to $35.00. The price reported above reflects the weighted average sale price. The Reporting Person herebyundertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-20-008833 · edgar.xml · derivative · entry 4 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 10,000 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. F4 · derivative.exercise_date: This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $37.47 | $374,700.00 |
DisclosureSEC source: 0001179110-20-008833 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,373 F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 10,000 | $16.51 | $165,100.00 |
DisclosureSEC source: 0001179110-20-008833 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:32 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,000 | $32.22 | $96,660.00 |
DisclosureSEC source: 0001179110-20-008367 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,373 F1 · security: The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:17 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 151 | $25.28 | $3,817.28 |
DisclosureSEC source: 0001179110-20-005605 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · EVP/Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,373 F1 · kind: The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 6, 2020. The sales do not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 21:34 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 622 | $26.95 | $16,762.90 |
DisclosureSEC source: 0001179110-20-001370 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,524 F2 · kind: The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2020. The sales do not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $26.42 to $26.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 21:34 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 69,556 | $0.00 Strike: $28.05 | $0.00 |
DisclosureSEC source: 0001179110-20-001370 · edgar.xml · derivative · entry 3 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,556 Underlying: Common Stock · 69,556 shares Expires 2030-02-05 F4 · derivative.exercise_date: This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 21:34 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 11,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001370 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,146 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 22:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,549 | $26.54 | $147,287.66 |
DisclosureSEC source: 0001179110-20-001026 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,553 F3 · kind: The sales reported in this Form 4 were effected pursuant to an durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on January 31, 2020. The sales do not represent a discretionary trade by the Reporting Person. F2 · balance_after: Such amount includes common stock received by the Reporting Person in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023, which was previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 8, 2019. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 22:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionRestricted Stock Units · Derivative | 17,977 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001026 · edgar.xml · derivative · entry 3 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which vested in full on January 31, 2020. F4 · derivative.exercise_date: The restricted stock unit award vested in full on January 31, 2020. F4 · derivative.expiration_date: The restricted stock unit award vested in full on January 31, 2020. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 22:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 17,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001026 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which vested in full on January 31, 2020. F2 · balance_after: Such amount includes common stock received by the Reporting Person in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, which is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023, which was previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 8, 2019. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:37 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantRestricted Stock Units · Derivative | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001684 · edgar.xml · derivative · entry 2 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Underlying: Common Stock · 8,125 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of common stock of Editas Medicine, Inc. F3 · derivative.exercise_date: The restricted stock unit award is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023. Shares will be delivered to the Reporting Person when units vest. F3 · derivative.expiration_date: The restricted stock unit award is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023. Shares will be delivered to the Reporting Person when units vest. Read SEC document |
| February 06, 2019 Filed Feb 9, 2019 00:37 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 48,750 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0001179110-19-001684 · edgar.xml · derivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2029-02-05 F1 · derivative.exercise_date: This option was granted on February 6, 2019 and is scheduled to vest over four years in equal monthly installments beginning on February 6, 2019 through February 6, 2023. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 22:29 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantRestricted Stock Units · Derivative | 17,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001235 · edgar.xml · derivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,977 Underlying: Common Stock · 17,977 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of common stock of Editas Medicine, Inc. F2 · derivative.exercise_date: The restricted stock unit award is scheduled to vest in its entirety on January 31, 2020, subject to acceleration in specified circumstances. Vested shares will be delivered to the Reporting Person on January 31, 2020. F2 · derivative.expiration_date: The restricted stock unit award is scheduled to vest in its entirety on January 31, 2020, subject to acceleration in specified circumstances. Vested shares will be delivered to the Reporting Person on January 31, 2020. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-18-008611 · edgar.xml · derivative · entry 3 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 10,000 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018. F3 · derivative.exercise_date: This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $35.98 | $359,800.00 |
DisclosureSEC source: 0001179110-18-008611 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.62 to $36.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 10,000 | $16.51 | $165,100.00 |
DisclosureSEC source: 0001179110-18-008611 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:31 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-18-007566 · edgar.xml · derivative · entry 3 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 10,000 shares Expires 2026-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018. F2 · derivative.exercise_date: This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:31 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0001179110-18-007566 · edgar.xml · nonDerivative · entry 2 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:31 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 10,000 | $16.51 | $165,100.00 |
DisclosureSEC source: 0001179110-18-007566 · edgar.xml · nonDerivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 23, 2018. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 22:23 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $36.67 | $0.00 |
DisclosureSEC source: 0001179110-18-001907 · edgar.xml · derivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2028-02-06 F1 · derivative.exercise_date: This option was granted on February 7, 2018 and is scheduled to vest over four years in equal monthly installments beginning on February 7, 2018 through February 7, 2022. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:14 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001179110-17-003788 · edgar.xml · derivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-02-28 F1 · derivative.exercise_date: This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 21:06 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $16.51 | $0.00 |
DisclosureSEC source: 0001179110-16-029608 · edgar.xml · derivative · entry 1 Albright Charles · CIK 0001682323 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2026-09-08 F1 · derivative.exercise_date: This option was granted on September 9, 2016 and is scheduled to vest over four years with 25% of the shares scheduled to vest on August 22, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through August 22, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.